RE: Novartis and Legend Biotech Sign Exclusive License Agreemen Onc has been involved with CAR-t opportunities for over a year.
They have 3 potential phase 3 co- development with Roche.
The PanCan project has been re- evaluated, yet the $5 million grant still intact.
Beyond that all guesswork.
We are told " multiple discussions with multiple potential pharma partners"
So!
with the recent strong evidence from the Roche/ Onc , " goblet" trials.
There is no gas left in the tank. Time to partner up or complete sale.
The SP is well bellow any sense of reason.
The delays of phase 3 , are mostly to blame.
As far as we can read, PanCan reevaluated their programs & not related to Pela or Onc.
Regardless that news is certainly difficult.
bottom line?
We need some positive business development news.
management knows that. The analysts know that.
Time for a paradigm shift.
Move Andrew De. Into overall presidential position.
" Onc can focuse on becoming a business driven company, to move Pela into the approval stage".